-transparent.png){kind=logo}
In the present study we have measured in parallel thyrotrophin binding inhibiting immunoglobulins (TBII) and thyroid adenylate cylase stimulating immunoglobulins (TACSI) in patients with Graves' disease (GD) both before and during long-term antithyroid treatment. A statistical model based on the calculation of the differences (TACSI-TBII) is presented, comparing the changes in this parameter to the analytical variation. The correlation between TBII and TACSI in 52 patients with GD before treatment was: r = 0.58, P less than 0.0001. During long-term antithyroid treatment of GD the 2 activities changed in parallel in 39 of 45 patients followed. In a few patients discrepancies were observed, and 1 patient, initially TACSI positive, developed adenylate cyclase inhibiting IgG during treatment but without detectable TBII. In conclusion, 1) TBII and TACSI are significantly correlated in patients with GD both before and during long-term antithyroid treatment, 2) in some patients discrepancies between TBII and TACSI suggest, that these IgGs are heterogeneous with varying capacity for stimulation of the adenylate cyclase and receptor binding, and 3) adenylate cyclase inhibitory IgG without TBII activity was demonstrated in GD.
H Bliddal, and
K Bech, and
P Hyltoft Petersen, and
K Siersbaek-Nielsen, and
T Friis
May 1985,
Taiwan yi xue hui za zhi. Journal of the Formosan Medical Association,
H Bliddal, and
K Bech, and
P Hyltoft Petersen, and
K Siersbaek-Nielsen, and
T Friis
February 1980,
Clinical endocrinology,
H Bliddal, and
K Bech, and
P Hyltoft Petersen, and
K Siersbaek-Nielsen, and
T Friis
April 1983,
The Journal of endocrinology,
H Bliddal, and
K Bech, and
P Hyltoft Petersen, and
K Siersbaek-Nielsen, and
T Friis
January 2006,
Endokrynologia Polska,
H Bliddal, and
K Bech, and
P Hyltoft Petersen, and
K Siersbaek-Nielsen, and
T Friis
March 2023,
Best practice & research. Clinical endocrinology & metabolism,
H Bliddal, and
K Bech, and
P Hyltoft Petersen, and
K Siersbaek-Nielsen, and
T Friis
November 1979,
FEBS letters,
H Bliddal, and
K Bech, and
P Hyltoft Petersen, and
K Siersbaek-Nielsen, and
T Friis
June 1980,
Lancet (London, England),
H Bliddal, and
K Bech, and
P Hyltoft Petersen, and
K Siersbaek-Nielsen, and
T Friis
February 1987,
Zhonghua nei ke za zhi,
H Bliddal, and
K Bech, and
P Hyltoft Petersen, and
K Siersbaek-Nielsen, and
T Friis
October 1979,
Clinical endocrinology,
H Bliddal, and
K Bech, and
P Hyltoft Petersen, and
K Siersbaek-Nielsen, and
T Friis
May 1995,
Clinical endocrinology,
